Equitable Access to New HIV Treatment And Prevention Options Is Needed Across Payers

For a variety of reasons, many individuals with acute and chronic health concerns do not take their medications daily, including people living with HIV on antiretroviral therapy (ART) and people who are using pre-exposure prophylaxis (PrEP). Longer-acting (LA) medications do not require daily pill taking and are generally effective for a month or longer, requiring less frequent administration. LA options are becoming available for ART as treatment and for prevention as PrEP. LA-ART and LA-PrEP have the potential to transform HIV treatment and prevention, but for this promise to be realized, these products must be available, affordable, and readily accessible.

Read more here.